University of California, San Francisco, Department of Neurological Surgery, United States.
Department of Radiation and Cellular Oncology, The University of Chicago, United States.
J Neurol Sci. 2017 Sep 15;380:250-255. doi: 10.1016/j.jns.2017.07.048. Epub 2017 Aug 1.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.
胶质母细胞瘤（GBM）是 55 岁以上成年人中最常见的原发性恶性脑肿瘤。诊断为 GBM 的患者的中位年龄为 64 岁，75 岁至 85 岁患者的发病率增加。由于与年龄相关的和/或医学合并症的频率较高，老年 GBM 患者的最佳治疗模式仍在不断发展。由于老年 GBM 患者预期持续治疗反应和/或良好结局的可能性降低，他们历来被排除在更大规模的对照临床试验之外。在这里，我们强调了目前针对老年 GBM 患者的手术、放射治疗和全身治疗方式的治疗考虑因素，并考虑了改善这一患者群体未来临床结果的措施。
